Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors.
Animals
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Drug Resistance, Neoplasm
/ drug effects
Humans
Immunotherapy
/ methods
Lymphoma, B-Cell
/ drug therapy
Multiple Myeloma
/ drug therapy
Proto-Oncogene Proteins c-bcl-2
/ antagonists & inhibitors
Tumor Microenvironment
/ drug effects
B-cell lymphoma-2 family
BCL-2 family protein inhibitors
Multiple myeloma
Personalized medicine
Targeted treatment
Journal
Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
04
10
2020
revised:
08
03
2021
accepted:
10
03
2021
pubmed:
21
3
2021
medline:
15
9
2021
entrez:
20
3
2021
Statut:
ppublish
Résumé
Multiple myeloma (MM) is a biologically complex hematological disorder defined by the clonal proliferation of malignant plasma cells producing excessive monoclonal immunoglobulin that interacts with components of the bone marrow microenvironment, resulting in the major clinical features of MM. Despite the development of numerous protocols to treat MM patients, this cancer remains currently incurable; due in part to the emergence of resistant clones, highlighting the unmet need for innovative therapeutic approaches. Accumulating evidence suggests that the survival of MM molecular subgroups depends on the expression profiles of specific subsets of anti-apoptotic B-cell lymphoma (BCL)-2 family members. This review summarizes the mechanisms underlying the anti-myeloma activities of the potent BCL-2 family protein inhibitors, individually or in combination with conventional therapeutic options, and provides an overview of the strong rationale to clinically investigate such interventions for MM therapy.
Identifiants
pubmed: 33741332
pii: S0006-2952(21)00122-2
doi: 10.1016/j.bcp.2021.114526
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins c-bcl-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114526Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.